Evolv Technologies Holdings (EVLV) is back in focus after the US Department of Homeland Security granted SAFETY Act Designation to its AI-powered bag screening product, Evolv eXpedite, classifying it as a Qualified Anti-Terrorism Technology.

The DHS recognition arrives after a 90 day share price return of 19.18% and a 1 year total shareholder return of 20.59%, even though the year to date share price return is down 9.10%. This suggests that recent momentum has picked up alongside contract renewals and product milestones.

If this kind of security and AI story interests you, it could be a good moment to broaden your search with our screener of 61 profitable AI stocks that aren't just burning cash

With Evolv trading at US$6.09, carrying a loss of US$36.46 million but sitting at a roughly 34% discount to the US$10.13 analyst price target, is there still a buying opportunity here, or has the market already priced in future growth?

Most Popular Narrative: 39.1% Undervalued

At a last close of $6.09 versus a fair value narrative of $10.00, the story on Evolv is built around recurring contracts and operating discipline.

The increasing prevalence of large multi-year contracts with public school systems and hospitals driven by heightened public safety concerns in high-density environments is expanding Evolv's total addressable market and should support outsized revenue growth over the coming years. Growing customer adoption and frequent upgrades to newer platforms like Gen2 and eXpedite reflect a successful technology road map that is boosting customer retention rates and fostering longer-term subscription commitments, positively impacting both ARR and net margins.

Curious what kind of revenue run rate, margin lift, and future earnings multiple are baked into that $10.00 fair value? The narrative leans on ambitious growth, richer subscription economics, and a premium valuation multiple normally reserved for market favorites. Want to see which specific assumptions have to line up for that story to hold?

Result: Fair Value of $10.00 (UNDERVALUED)

However, that story can unravel if gross margins stay pressured by hardware heavy direct sales or if customer expansion across schools, hospitals, and venues slows meaningfully.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: What The Ratios Are Saying

The story built around a US$10.00 fair value leans on future earnings, but today the market is still trading Evolv on sales. At a P/S of 6.8x versus a US Electronic industry average of 3.2x and a peer average of 8.3x, the stock sits between sector and peer benchmarks while the fair ratio of 3.4x suggests the market could move closer to a much lower sales multiple over time. For investors, that gap can either look like valuation risk if growth stalls or headroom if the story plays out, so which side of that tradeoff do you think fits your own expectations?

Next Steps

Given the mix of optimism and concern in this story, it makes sense to move quickly, verify the underlying data, and determine your own view using the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If Evolv has your attention, do not stop here. The next smart move is to scan a wider set of opportunities before the crowd turns to them.

• Target stability and income by checking companies offering robust payouts in the 8 dividend fortresses.
• Hunt for quality at a reasonable price by running your filters through the 44 high quality undervalued stocks.
• Prioritize resilience by focusing on companies screened in the 70 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.